94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
SYSTEMATIC REVIEW article
Front. Cardiovasc. Med.
Sec. Heart Failure and Transplantation
Volume 12 - 2025 | doi: 10.3389/fcvm.2025.1385061
This article is part of the Research Topic Worsening Heart Failure: Challenges, Treatments, Future Perspectives View all 5 articles
Efficacy and safety of Dengzhan Shengmai capsule in the treatment of chronic heart failure: a systematic review and meta-analysis
Provisionally accepted- Hunan University of Chinese Medicine, Changsha, China
Background: Dengzhan Shengmai Capsule (DZSMC) is a potential treatment for chronic heart failure (CHF). However, its specific benefits in the treatment of CHF remain unclear.Methods: Related randomized controlled trials were searched in eight databases up to January 28, 2025, and included studies were determined according to the inclusion criteria. Subsequently, the basic characteristics and data from these studies were recorded useing Excel 2010. Outcome-related data were subsequently imported into Revman 5.3 for meta-analysis.Results: Fifteen randomized controlled trials with 1606 patients were included in this meta-analysis. The results showed that compared to conventional treatment group, DZSMC combination group significant improved the clinical effective rate [RR=1.21, 95% CI (1.16,1.26), P<0. 00001], brain natriuretic peptide (BNP) [MD=-112.60, 95%CI (-212.23, -12.96), P=0.03], N-terminal pro-B-type natriuretic peptide (NT-proBNP) [MD=-88.27, 95%CI (-108.11, -68.42), P<0.00001], left ventricular ejection fraction (LVEF) [MD=6.42, 95% CI (5.57, 7.27), P<0.00001], left ventricular end-diastolic diameter (LVEDD) [MD=-5.72, 95% CI (-7.56, -3.87), P<0.00001], left ventricular end-systolic diameter (LVESD) [MD=-5.53, 95% CI (-7.41, -3.26), P<0.00001], left ventricular end-systolic volume (LVESV) [MD=-20.71, 95% CI (-34.59, -6.82), P=0.003], and 6-minute walk test [MD=51.90, 95%CI (19.08, 84.72), P=0.002], while adverse events had no significant difference [RR=0.70, 95%CI (0.42, 1.17), P=0.17]. Funnel plots indicated no publication bias for BNP, NT-proBNP, LVEF, and LVESD, while potential bias was observed for other outcomes.Conclusion: DZSMC effectively improves clinical symptoms, cardiac function, and ventricular remodeling in CHF patients, with good safety, making it a potential adjuvant therapy for CHF. However, further research is needed to explore the long-term safety of DZSMC in order to enrich clinical evidence.
Keywords: Dengzhan Shengmai capsule, chronic heart failure, cardiac function, Systematic review, Meta-analysis
Received: 11 Feb 2024; Accepted: 10 Feb 2025.
Copyright: © 2025 Lu, Yu, Dai, Hu and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Shenghua Lu, Hunan University of Chinese Medicine, Changsha, China
Jianhe Liu, Hunan University of Chinese Medicine, Changsha, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.